Peptides Weight LossMetabolic

Retatrutide

Reta · Triple-G

Triple-agonist (GLP-1/GIP/glucagon) investigational peptide; very potent weight loss.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Pharmacokinetic summary

Model tier: Advanced (t½ + Cmax + Tmax + F)
Half-life: 6 days
Cmax: 11495.37 nmol/L
Tmax: 1.7 days
Bioavailability: 80%
Typical dose: 1–12 mg

Related compounds

Semaglutide Injection (Ozempic/Wegovy)

Long-acting GLP-1 receptor agonist for type 2 diabetes and weight loss; weekly injection.

Semaglutide Oral (Rybelsus)

Oral semaglutide with very low bioavailability; taken fasting.

Tirzepatide (Mounjaro)

Dual GIP/GLP-1 agonist for weight loss and diabetes; weekly injection, strong efficacy.

Protocols featuring Retatrutide

Retatrutide Protocol (24 weeks)

Investigational triple-agonist (GLP-1/GIP/glucagon) Phase 2 trial titration: 2 → 4 → 8 → 12 mg weekly, escalating every 4 weeks to the 12mg maintenance dose.

Comments

Loading comments…